Emulsifiers and gut inflammation in mice

Overview

Chassaing B et al.. Nature 2015 · PMID 25731162 · DOI 10.1038/nature14232

Two common emulsifiers caused gut inflammation and metabolic problems in mice.

Does the study support the specific claim? Partly · Methodological quality: moderate

Original publication

Plain-language summary

Scientific in-depth review

1. Full reference

Authors

Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, Gewirtz AT

Journal

Nature

Year

2015

Identifier

PMID 25731162 DOI 10.1038/nature14232 · PMC4910713

Verification

verified – PubMed E-utilities efetch, 2026-10-25

Retracted

no

Corrections

PubMed lists: ErratumIn (Nature. 2016 Aug 11;536(7615):238. doi: 10.1038/nature18000.)

Extent checked

full text

Conflicts of interest and funding

NIH grants DK099071 and DK083890; first author held a Crohn's and Colitis Foundation of America fellowship. No competing-interest statement in the available full text.

2. Research question

Do emulsifiers promote gut inflammation and metabolic syndrome via microbiota?

3. Study design and population

Study design

Animal study – Controlled mouse experiments: wild-type C57BL/6 and Swiss-Webster mice and colitis-prone IL10-/- and TLR5-/- mice given carboxymethylcellulose (CMC) or polysorbate-80 (P80) for 12 weeks; germ-free mice and faecal microbiota transplantation; dose-finding (0.1-1.0%); littermate-split cage designs.

Population

Mice (mostly 4 weeks old at start; also 4-month-old mice); male or female within experiments

Country

USA

Period

Not stated (published 2015)

Sample size

Typically n=20 per group for main WT/IL10-/- experiments; n=3-15 in sub-experiments (e.g. n=5 for chow and dose-finding, n=3 for microbiota transplant)

Inclusion and exclusion criteria

Mice developing colitis (faecal lipocalin-2 >=500 ng/g) were excluded from metabolic-syndrome analyses.

4. Methods and endpoints

Exposure / intervention

CMC or P80 at 1.0% (w/v or v/v) in drinking water or chow; lower doses 0.1% and 0.5%; sodium sulfite as non-emulsifier additive control

Comparator

Same water/chow without emulsifier

Endpoints

Low-grade inflammation, obesity/metabolic syndrome, colitis, microbiota

Statistical methods

t-tests and one- or two-way ANOVA with Sidak or Bonferroni correction (GraphPad Prism); 16S rRNA sequencing with UniFrac PCoA; nearest-shrunken-centroid classification.

5. Actual results

Results

Emulsifiers reduced the bacteria-epithelium distance by >50% with thinner mucus, increased mucosa-adherent bacteria >2-fold, altered microbiota composition, raised faecal bioactive LPS and flagellin and gut permeability. In IL10-/- and TLR5-/- mice they increased colitis incidence and severity (faecal Lcn-2 ~10-fold higher); WT mice showed low-grade inflammation without overt colitis. WT mice had modest weight gain, increased fat mass, increased food intake and impaired glycaemic control; effects seen with 1.0% in chow, from 0.1% (P80) and 0.1-0.5% (CMC), persisted >=6 weeks after stopping, absent with sodium sulfite. No effects in germ-free mice; transfer of microbiota from treated mice to germ-free mice transferred encroachment, inflammation, adiposity and dysglycaemia.

Absolute risks

not applicable

Authors' conclusion

In mice, low concentrations of CMC and P80 induced low-grade inflammation and obesity/metabolic syndrome in WT hosts and robust colitis in predisposed hosts, via microbiota changes; broad use of emulsifiers might be contributing to increased obesity/metabolic syndrome and chronic inflammatory diseases; additional studies are needed to determine effects on human health. The metabolic effect appeared driven by increased food intake.

6. Strengths

• Multiple mouse strains and vivaria; littermate-split designs to control cage effects
• Germ-free and microbiota-transplant experiments establish microbiota dependence in mice
• Dose-finding down to 0.1%; reversibility and non-emulsifier control (sodium sulfite)

7. Weaknesses

• Animal model; human relevance unknown (authors)
• Exposure 0.1-1.0% in all drinking water or chow; relation to actual human intake not quantified
• Treatments not blinded; histology blinding not reported
• Some sub-experiments very small (n=3-5)
• Colitic mice excluded from metabolic analyses
• Only two emulsifiers tested; findings cannot be generalised to all emulsifiers

8. Risk of bias

Orienting tool

none applicable (animal experimental study; SYRCLE-oriented structured judgement)

Type of assessment

structured assessment based on the full text by a single reviewer (no formal double review)

Full formal assessment

no

Overall risk of bias

some concerns

Rationale

No standard tool fits a mechanistic animal study; structured single-reviewer judgement from the full text. Internal validity moderate; external validity to humans low. A complete formal assessment requires two independent reviewers.

Full-text review (25 October 2026): Added doses (1.0% and 0.1-0.5%), duration (12 weeks), group sizes (n=3-20), strains, germ-free/transplant results, increased food intake as driver of adiposity, unblinded exposure, exclusion of colitic mice from metabolic analyses, NIH funding. Structured SYRCLE-oriented judgement added (overall some_concerns, previously not_assessable); bias_risk dimension set to some_concerns.

9. Assessment of the statistical interpretation

Large, reproducible effects in mice with multiple-comparison-corrected tests; small groups in some sub-experiments. Effect sizes cannot be translated to human risk.

10. Relevance to the specific claim

Mechanistic basis for C-UPF-06 and C-UPF-05.

11. Independent contrary findings

Human evidence limited (A-UPF-16).

12. Transferability to Germany and Europe

Moderate.

13. Overall methodological judgement

Strong, well-replicated mechanistic evidence in mice that CMC and P80 can disturb gut microbiota and mucus, promote low-grade inflammation and colitis in susceptible mice, and increase food intake and adiposity. It does not show effects in humans.

14. Open questions

Human relevance.

15. Linked fact checks

• Higher ultra-processed food intake raises the risk of inflammatory bowel disease (PURE study: HR 1.82 for >=5 servings/day). – Studies with mixed or unclear results
• Industrial emulsifiers such as carboxymethylcellulose erode the gut's protective mucus layer and drive inflammation and metabolic disease. – Studies supporting the claim

Use by the Tayebat archive

Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.

What the archive says about the study

Synthetic emulsifiers (CMC, P80) alter gut microbiota and drive intestinal inflammation, colitis and metabolic syndrome in mice.

A. What was actually studied?

Emulsifiers in mice.

B. What did the authors find?

As above.

C. What conclusions do the authors themselves draw?

May contribute to human disease.

D. What does the archive derive from it?

Narrative: emulsifiers 'erode the protective mucus layer'; mechanisms 'no longer mysterious'.

E. Is this derivation scientifically justified?

The featured card correctly says 'in mice'. The narrative claim that emulsifiers 'erode the protective mucus layer' in people and that mechanisms are 'no longer mysterious' generalises mouse findings to humans; the authors themselves call for human studies. In germ-free mice emulsifiers did not thin the mucus, so the effect depends on the microbiota.

Adequacy of the interpretation (by the archive)

partly correct but over-interpreted